Drugs / IBB0979
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05991583 | Jul 2023 → Nov 2025 overdue | cancer | SUNHO（China）BioPharmaceutical CO., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07076095 | Aug 2025 → Aug 2028 expected | small cell lung carcinoma | SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBB0979 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05991583 ↗ |
| Route | Subcutaneous | “IBB0979 should be subcutaneous injected，qw” NCT05991583 ↗ |